NYSE:ANVS Annovis Bio (ANVS) Stock Price, News & Analysis $1.15 +0.05 (+4.91%) Closing price 09/18/2026 03:59 PM EasternExtended Trading$1.14 -0.01 (-0.87%) As of 09/18/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Annovis Bio Stock (NYSE:ANVS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Annovis Bio alerts:Sign Up Key Stats Today's Range$1.09▼$1.1650-Day Range$1.08▼$1.8952-Week Range$1.04▼$5.50Volume677,303 shsAverage Volume1.26 million shsMarket Capitalization$49.25 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingHold Company Overview Annovis Bio, Inc. (NYSE: ANVS) is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease. The company is headquartered in Berwyn, Pennsylvania, and its research centers on therapies intended to address mechanisms associated with the accumulation of toxic proteins in the brain. Annovis Bio’s lead investigational product is buntanetap, formerly known as ANVS401. The orally administered small-molecule drug is designed to inhibit the production of multiple neurotoxic proteins implicated in neurodegenerative disorders. The company has evaluated buntanetap in clinical studies involving patients with Alzheimer’s and Parkinson’s disease and continues to assess its potential as a disease-modifying treatment. Annovis Bio was founded by Maria L. Maccecchini, Ph.D., who serves as the company’s chief executive officer and has led its development programs. The company does not currently have an approved commercial product and is focused primarily on research, clinical development, and advancing its investigational therapies through the regulatory process.AI Generated. May Contain Errors. Read More Annovis Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreANVS MarketRank™: Annovis Bio scored higher than 51% of companies evaluated by MarketBeat, and ranked 527th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingHold Consensus RatingAnnovis Bio has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAnnovis Bio has a consensus price target of $12.00, representing about 939.9% upside from its current price of $1.15.Amount of Analyst CoverageAnnovis Bio has only been the subject of 4 research reports in the past 90 days.Read more about Annovis Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Annovis Bio are expected to grow in the coming year, from ($1.32) to ($0.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Annovis Bio is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Annovis Bio is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnnovis Bio has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Annovis Bio's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.79% of the float of Annovis Bio has been sold short.Short Interest Ratio / Days to CoverAnnovis Bio has a short interest ratio ("days to cover") of 9.59.Change versus previous monthShort interest in Annovis Bio has recently increased by 0.51%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnnovis Bio does not currently pay a dividend.Dividend GrowthAnnovis Bio does not have a long track record of dividend growth. News and Social Media3.0 / 5News SentimentN/A News SentimentAnnovis Bio has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Annovis Bio this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for ANVS on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat Follows6 people have added Annovis Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Annovis Bio insiders have not sold or bought any company stock.Percentage Held by Insiders20.80% of the stock of Annovis Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions15.83% of the stock of Annovis Bio is held by institutions.Read more about Annovis Bio's insider trading history. Receive ANVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Annovis Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANVS Stock News HeadlinesAnnovis Bio consensus price target lowered by 16.67% to $10.71September 15, 2026 | msn.comAnnovis Bio (NYSE:ANVS) Downgraded to "Strong Sell" Rating by Wall Street ZenSeptember 12, 2026 | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.September 19 at 1:00 AM | InvestorPlace (Ad)Analysts Are Bullish on Top Healthcare Stocks: Annovis Bio (ANVS), AbbVie (ABBV)September 5, 2026 | theglobeandmail.comAnnovis to Host Corporate Update Webinar on September 2, 2026August 25, 2026 | globenewswire.comAnnovis Provides Corporate Updates and Second Quarter 2026 Financial ResultsAugust 14, 2026 | globenewswire.comAnnovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s DiseaseJuly 7, 2026 | markets.businessinsider.comAnnovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer's DiseaseJuly 7, 2026 | globenewswire.comSee More Headlines ANVS Stock Analysis - Frequently Asked Questions How have ANVS shares performed this year? Annovis Bio's stock was trading at $3.43 on January 1st, 2026. Since then, ANVS shares have decreased by 66.4% and is now trading at $1.1540. How were Annovis Bio's earnings last quarter? Annovis Bio, Inc. (NYSE:ANVS) released its quarterly earnings results on Friday, August, 14th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.05. When did Annovis Bio IPO? Annovis Bio (ANVS) raised $12 million in an initial public offering on Thursday, November 18th 2021. The company issued 2,000,000 shares at a price of $6.00 per share. Who are Annovis Bio's major shareholders? Top institutional investors of Annovis Bio include Empery Asset Management LP (6.93%), BlackRock Inc. (0.72%), First National Trust Co (0.17%) and GSA Capital Partners LLP (0.14%). Insiders that own company stock include Michael B Hoffman and Maria-Luisa Maccecchini. View institutional ownership trends. How do I buy shares of Annovis Bio? Shares of ANVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Annovis Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Annovis Bio investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD) and CrowdStrike (CRWD). Company Calendar Last Earnings8/14/2026Today9/19/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 8 days, ANVS's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSE:ANVS CIK1477845 Webwww.annovisbio.com Phone(484) 875-3192FaxN/AEmployees7Year Founded2008Price Target and Rating Average Price Target for Annovis Bio$12.00 High Price Target$17.00 Low Price Target$7.00 Potential Upside/Downside+939.9%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$28.85 million Net MarginsN/A Pretax MarginN/A Return on Equity-685.98% Return on Assets-258.77% Debt Debt-to-Equity RatioN/A Current Ratio3.47 Quick Ratio3.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.64 per share Price / Book1.80Miscellaneous Outstanding Shares42,680,000Free Float33,802,000Market Cap$49.25 million OptionableOptionable Beta1.24 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NYSE:ANVS) was last updated on 9/19/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annovis Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
